Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig + JNJ-86974680 in advanced prostate cancer
NCT07319871Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of pasritamig and jnj-86974680 in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events by Severity and Number of Participants With Dose-Limiting Toxicity. Started Jan 2026; status: recruiting.
02
Drugs
pasritamigjnj-86974680
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07319871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319871.